rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

David Michael Clark

Chief People Officer

Company insider

Files Form 4 as: Chief People Officer, Amicus Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
77
Buys
0
Sells
12
Bought
$0
Sold
$2.0M
Companies
1
Companies where not an officer
0
First trade
9 Oct 2018
Last trade
27 Apr 2026
Last filed
27 Apr 2026

Companies traded

Where they are an officer
Amicus TherapeuticsOfficer · Biotechnology · last 27 Apr 20260 buys · 12 sells

Activity over time

1 Nov 2024 – 1 Oct 2026
20Nov 24May 25Nov 25Apr 26Oct 26

Buys above the line, sells below, each month.

Every trade

TradedCompanyWhatAmount
27 Apr 2026filed 27 Apr 2026Amicus TherapeuticsBiotechnologySEC FORM 4 Code D$3.2M221,811 at $14.50filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—84,842filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—77,134filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—84,842filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—77,134filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—91,439filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—108,266filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—105,388filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—83,221filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivativeSEC FORM 4 Code D—125,430filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—91,439filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—108,266filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—105,388filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—83,221filing
27 Apr 2026filed 27 Apr 2026Amicus Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code D—125,430filing
27 Apr 2026filed 27 Apr 2026Amicus TherapeuticsSEC FORM 4 Code D$3.2M221,811 at $14.50filing
3 Jan 2026filed 6 Jan 2026Amicus TherapeuticsBiotechnologySEC FORM 4 Code F$264K18,498 at $14.27filing
3 Jan 2026filed 6 Jan 2026Amicus TherapeuticsSEC FORM 4 Code F$264K18,498 at $14.27filing
2 Jan 2026filed 6 Jan 2026Amicus TherapeuticsBiotechnologySEC FORM 4 Code F$77K5,381 at $14.27filing
2 Jan 2026filed 6 Jan 2026Amicus TherapeuticsSEC FORM 4 Code F$77K5,381 at $14.27filing

News

No headline names them, or the companies they trade most, lately.

Sectors

Not placed12

Buys in green, sells in red, by the company’s sector.

Related people

Burke W. WhitmanDirector · Director at Amicus Therapeutics, filing Form 4 there in the last year
Margaret G. McGlynnDirector · Director at Amicus Therapeutics, filing Form 4 there in the last year
Craig A. WheelerDirector · Director at Amicus Therapeutics, filing Form 4 there in the last year
Glenn SblendorioDirector · Director at Amicus Therapeutics, filing Form 4 there in the last year
Michael RaabPresident & CEO · Director at Amicus Therapeutics, filing Form 4 there in the last year